NCA029
Based on 1 Customer Validation
NCA029 is a potent and selective homo sapiens caseinolytic protease P (HsClpP) activator with an EC50 of 0.15 μM. NCA029 acts on HsClpP to activate an ATF3-dependent integrative stress response, leading to colon cancer cell death.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.24%
- CAS No.: 3032667-94-7
- Formule: C22H20F3N3O
- Masse moléculaire:399.41
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DLD-1 | IC50 |
3.1 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| H9c2 | IC50 |
60.6 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against rat H9c2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against rat H9c2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| HCT-116 | IC50 |
1 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| HCT-15 | IC50 |
3.5 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| HEK293 | IC50 |
78.1 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| L02 | IC50 |
64.1 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| SW480 | IC50 |
5.4 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
| SW-620 | IC50 |
1.5 μM
Compound: 3-19e; NCA029
|
Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method
|
[PMID: 38329974] |
NCA029 inhibits human colon adenocarcinoma (COAD) cell lines with IC50 values of 1.1 μM, 1.5 μM, 3.5 μM, 5.4 μM, and 3.1 μM for HCT116, SW620, HCT15, SW480, and DLD-1, respectively[1].
NCA029 causes an increase in intracellular ROS levels in HCT116 cells in a dose-dependent manner, indicating impaired respiratory chain activity[1].
NCA029 (0.5-2 μM; 48 h) inhibits tumor cell proliferation and metastasis[1].
NCA029 (0.5-2 μM; 48 h) dose-dependently induces apoptosis and arrests cells with G2/M phase in HCT116 cells[1].
NCA029 (0.5-2 μM) dose-dependently reduces the expression of SDHB and up-regulated the expression of the pro-apoptotic protein BAX, while down-regulating the expression of the antiapoptotic protein Bcl-2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:48 h
-
Result:Resulted in a dose-dependent reduction in HCT116 clone formation ability.
-
Cell Line:HCT116 cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:48 h
-
Result:Significantly increased the number of cells in the G2 phase.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude mice bearing HCT116 tumors[1]
-
Dosage:1.25, 2.5, and 5 mg/kg
-
Administration:intravenous administration; twice weekly; for 21 days
-
Result:Inhibited tumor growth in mice xenograft model.
Chemical Information
-
CAS No. 3032667-94-7
-
Appearance Oil
-
Masse moléculaire 399.41
-
Formule C22H20F3N3O
-
Color Colorless to light yellow
-
SMILES
N#CC1=CC=CC(CN2CCC=C(C2)C(NCC3=CC=C(C=C3)C(F)(F)F)=O)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 100 mg/mL (250.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5037 mL | 12.5185 mL | 25.0369 mL | 62.5923 mL |
| 5 mM | 0.5007 mL | 2.5037 mL | 5.0074 mL | 12.5185 mL | |
| 10 mM | 0.2504 mL | 1.2518 mL | 2.5037 mL | 6.2592 mL | |
| 15 mM | 0.1669 mL | 0.8346 mL | 1.6691 mL | 4.1728 mL | |
| 20 mM | 0.1252 mL | 0.6259 mL | 1.2518 mL | 3.1296 mL | |
| 25 mM | 0.1001 mL | 0.5007 mL | 1.0015 mL | 2.5037 mL | |
| 30 mM | 0.0835 mL | 0.4173 mL | 0.8346 mL | 2.0864 mL | |
| 40 mM | 0.0626 mL | 0.3130 mL | 0.6259 mL | 1.5648 mL | |
| 50 mM | 0.0501 mL | 0.2504 mL | 0.5007 mL | 1.2518 mL | |
| 60 mM | 0.0417 mL | 0.2086 mL | 0.4173 mL | 1.0432 mL | |
| 80 mM | 0.0313 mL | 0.1565 mL | 0.3130 mL | 0.7824 mL | |
| 100 mM | 0.0250 mL | 0.1252 mL | 0.2504 mL | 0.6259 mL |
NCA029 Related Classifications
HY-163319 Related Classifications
Powered by Bioz